{"name":"23andMe","slug":"23andme","ticker":"ME","exchange":"NASDAQ","domain":"23andme.com","description":"23andMe is a genomics and drug discovery company that offers direct-to-consumer genetic testing and has developed several therapeutic products. The company focuses on developing treatments for various diseases, including rare genetic disorders. 23andMe has a strong market position in the genomics and drug discovery sector.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Mark Jensen (Interim)","sector":"Genomics / Drug Discovery","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$100M","metrics":{"revenue":200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-01","label":"Levoleucovorin patent cliff ($100M at risk)","drug":"Levoleucovorin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"23ME-00610","genericName":"23ME-00610","slug":"23me-00610","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"23ME-00610","genericName":"23ME-00610","slug":"23me-00610","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-15","type":"regulatory","headline":"23andMe Receives FDA Clearance for New Genetic Health Risk Report","summary":"The FDA cleared 23andMe's new genetic health risk report for Bloom Syndrome, a rare genetic disorder.","drugName":"","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"23andMe Reports Third Quarter 2022 Financial Results","summary":"23andMe reported revenue of $283.5 million for the third quarter of 2022, a 25% increase from the same period in 2021.","drugName":"","sentiment":"neutral"},{"date":"2022-06-14","type":"deal","headline":"23andMe Partners with Pfizer to Develop New Therapies","summary":"23andMe partnered with Pfizer to develop new therapies for rare genetic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQa0RiR1QwdU1iWFp5VHprOUh5R3R5MGtvQktUSnRxemJtb0tNMFBsa1JSU3gyQVdBWUhQWG5RSWNvSEhTOVdYT3FBN0pkaktBNEFQZURZVEQ1U3VYeldEbWdzcFFHbnphVW9WQXFoX1V6YXB0em1jUVA2TURFWXlrOS1xbjQtZnRwc2hfY25fYk5BWVJZ0gGaAUFVX3lxTFA4Q18zYUVkT2ZqWlJ1dHVKVnNMRWhpTi0xcnM0UEJ3MUNvV2htTUVoR3VrMnY3RWdJeHhTY2ZvT0M4NTlIR1dSQXdJbG1UbEZpLVl6UGM2aHBsWExjZXptSEpubHg0NDBZTzNOUU9vQ0Z6U0NJQkRSMUl1WF9qeUtRRUJxQmk2WmE3dDFfVDktelpZREk4TkJkSWc?oc=5","date":"2026-02-15","type":"deal","source":"abcnews.com","summary":"Regeneron Pharmaceuticals to buy 23andMe for $256M - abcnews.com","headline":"Regeneron Pharmaceuticals to buy 23andMe for $256M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQSWZlck51dGVnNGt3WUFNaUE0YXU0bkR4N0pXSlVzaTBMYkdIWmkzZHFCcGxwbUFDOWlHWUE1bnJXSk9MOGh6UnhycWVoeGtJaXBaMW9scXN0QUVrdGg5bVc4RzJraExhc1hHVkhYbG5vR3R1WVktSkoxSk1jX1NLSw?oc=5","date":"2025-06-30","type":"trial","source":"NPR","summary":"Judge OKs sale of 23andMe — and its trove of DNA data — to a nonprofit led by its founder - NPR","headline":"Judge OKs sale of 23andMe — and its trove of DNA data — to a nonprofit led by its founder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNNmFJaTBTNUR5TTN1MmNpaEp0MEt4QnVYdDRraVkxaF85NHAyb3ZrZXUwa3RfYmcwRl9rNG1XT2hodFhyeTl0SER1d2FzZHhFaVV1SmloeDRQWlpvVGNPMW5YQ0Qyc1VkNHgwZGctMkhpd2NDaTFIb3kxMHQ4Ti1YXzZjZDY5RGUyQnRmblp1VWg?oc=5","date":"2025-05-29","type":"pipeline","source":"The New York Times","summary":"23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times","headline":"23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQWWdKREE2UHhfZ0ZqbkJNZWszUDZhY1JIZkNWcUJXVXdudUlFMEJaV19FS0JPMzJHQmxmNXl4NjM3NGItRHlRS2N5WUN2dnIzY2UyYy1QckZoWm43d1M2RlV4ZFBpYlBYSklDNkYwaWNlNnlqT2lWazUxLWRQbGpiU0RsRExVUGUwbDdhZFZXMFFiSEhSbVNZSEhsRVFoSlduc0FSdDZFaDd5aWN4T0RnT0dkTDlDelk?oc=5","date":"2025-05-20","type":"trial","source":"Malwarebytes","summary":"23andMe and its customers’ genetic data bought by a pharmaceutical org - Malwarebytes","headline":"23andMe and its customers’ genetic data bought by a pharmaceutical org","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFA5NEdMRVJzNHVmcXIwSjhpeWZwV2hod3lkV2FNRkNXaXFhQ3dFSFEyY3NRclVRaWZFTDZCaEdYRkNDaVpEV1JkUXlSWWFGMjVMTkozVXJ0MGZTVVpYWk5BWUNLcXJ1cWtrT19QaGgxemtRTlhLRzJMcVlNaHB5dw?oc=5","date":"2025-05-20","type":"trial","source":"Deseret News","summary":"23andMe sale: What will happen to the DNA data under Regeneron Pharmaceuticals - Deseret News","headline":"23andMe sale: What will happen to the DNA data under Regeneron Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQcVZWWHdsVElkTjgyN0FzUHhUSnYxSmhiNXZpMF91dlNQUnoyRlpOS2hDZkpLMGF4RWJOZ2p2X044RGhLWllKSXdSRGpONXFzbnlOS1h6UTFNMVlRRThiaDFiMkJ0UzBESWc2WkRnemQ5VG1yZ282bnZ3Rkg4Z1FQbmZUQXRjaFVoZzV0eFlMUU40TV9nck51SUZldkxTTGZ4M3FLM0lwamY5Mkpz0gGyAUFVX3lxTFBCTWxvYmlPUlJNX3FKSEpOYmNaMUhkRlJUcC1oZ3g2LUNnTHByVmFZYVB3aTZfYXpMSlhyZ0hMWkN5TFMwYy1lQ1Byb3BJeDRoQW9US1U5Q0Jsd1dzSVg2MTY1U3RvWnlRQWo1Mm5hN1JyWTcwSFFfUzVoN1hIdml0azhLSWtWc05tY3MzM3MxQUd1SHh3WmRmdU81dTNBbmFSbDFKYUZkZUtvUmVCQm4zU2c?oc=5","date":"2025-05-19","type":"trial","source":"CNBC","summary":"Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million - CNBC","headline":"Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOUEhjRWpvNHBYMEltS094ZGI5eUpiVE9aMVBhbHJHX0Jaa1l6dW93UC1FQ2dJeG5keS1vX0ZtcFZsQWJtMENRTUhJQzRCcGcxS3JCZGp0SnlyX1A3ODAtWWlaT3FMeWRwU1AtTFJyazdrWEdramszdWJPcHVCOWE3dlZEYlJLTlhTSjNJblY5M1E4WTFlQU02QmZ1M2lFUjdERXRJUnlhQ3hiQmNQOTdGVjg4MndaMjhKWktSR2o0M3hvQjF4WXNLVjNfdWRoVzRy?oc=5","date":"2025-05-19","type":"trial","source":"reuters.com","summary":"Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data - reuters.com","headline":"Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1yU25xVlk3MUtsVklnUzk0YlhpQmF3aFlNM0ZZUTZyNXNob3pGeUNkMWkycTdINGZBOEdwSVhra3hzUEJfZWJjZ2QwWjJxZjJSUkhVRVZyTmgwMHRDSDI3a05hcTNQbnByeDJrU2tYZ2FUZG42Z2I0NVJPd0lDUDg?oc=5","date":"2025-05-19","type":"pipeline","source":"qz.com","summary":"23andMe just got bought out of bankruptcy - qz.com","headline":"23andMe just got bought out of bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5nYWRmN0Z1ZzZNbURVSEIxYlViX1ptZVZXbVQ4TVBwNFZDSWdrMWhUbmpZeHJ6YlAzV2ZKNUlUdnZid1ljU2o3OXpUZUl0MFc4T1AyN1djTlNaWFRaSGU1ZHU2TDN0eTNtV1E4?oc=5","date":"2025-05-19","type":"deal","source":"CNN","summary":"Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million - CNN","headline":"Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNN0tkMHpNNjBNZGJ5SGdXVDJtYmQyVnk3V1BzQ1VRNVYzMDE4ZndTSnYwck1CTXBhaUFYeDZLMVlodG9DQXJXWllTRHpqUFo2eXExZ2FPRlk3dFktaXZIUkRmck00TV9aZUVzdk03aFZ2eklyX1ZoZC1fYzRwWkloU2tmQWNSTktvLVk2c3V3?oc=5","date":"2025-05-19","type":"deal","source":"Morning Brew","summary":"Pharma co. buys 23andMe and its DNA vault for $256 million - Morning Brew","headline":"Pharma co. buys 23andMe and its DNA vault for $256 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdXktVG5aczBobDloWU00ckRTRWJscHQ3akVvTlNuTDhJcDllc09kVS1lSUxkZWQ3R2pwMkpMM0hnY3JSbHR1QUFGUUtqWFYwYkF1MjBCTW1LRDk2QU8zelQ3ZGFRTEo1RTVtLWlVa1VjblQtVk1SSWE0MHdDOVZJMzU1Qm9QaE1zTXpXc0RTQmtQNWs1RDhqMGFsNi1MOWN3YlkwLXFVSQ?oc=5","date":"2025-05-19","type":"trial","source":"TechCrunch","summary":"Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M - TechCrunch","headline":"Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUWtVMEhaWDhLUm5ocGVaU0N5aUwyRXl0aFpfbXhHb1Bwd3ppbmpLbnFlVlh3a1JBX19iNUZINDAyNlRLWGg4N2JRV3EyVDg3RzFfWlo2aEs4SXFMWjllQklOYjgyaE45ekQ1TE5jMkt1ajJOWlF0alhQUkpmZWlwNEVkeTdBWlhXWWlrWkpDMFRla3gyaFNOZEJTNXRfbDRQXzRUSFJSN2JGN2ZaS0o0bkJUTjhkNllU?oc=5","date":"2025-05-19","type":"trial","source":"nypost.com","summary":"Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions - nypost.com","headline":"Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions","sentiment":"neutral"}],"patents":[{"drugName":"Levoleucovorin","drugSlug":"levoleucovorin","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Illumina","Invitae","Myriad Genetics"],"therapeuticFocus":["Rare Genetic Disorders","Genetic Health Risk Reports"],"financials":null,"yahoo":null}